MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Device: SenseWear Armband Gecko
Device: SenseWear Armband MF
Device: Actigraph GT9x wristband and waistband
Device: Garmin Vivofit 2 wristband
Device: SOMNOwatch plus EEG 6 sleep monitor
Other: Strength exercises
Other: Field-based exercise tests
Other: Laboratory-based exercise tests
First Posted Date
2015-12-02
Last Posted Date
2017-05-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
22
Registration Number
NCT02619357
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Phase 3
Terminated
Conditions
Pemphigus
Interventions
Drug: Ofatumumab
Drug: Acetaminophen/paracetamol
Drug: Antihistamine (cetirizine or equivalent)
Drug: Prednisone/Prednisolone
First Posted Date
2015-11-25
Last Posted Date
2017-06-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1
Registration Number
NCT02613910
Locations
🇺🇸

GSK Investigational Site, Ann Arbor, Michigan, United States

First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients

Phase 1
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: GSK3008348 Nebuliser solution
Drug: Placebo Nebuliser solution
First Posted Date
2015-11-23
Last Posted Date
2017-05-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
40
Registration Number
NCT02612051
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

Not Applicable
Completed
Conditions
Dentin Sensitivity
Interventions
Device: Stannous Fluoride dentifice
Other: Sodium Monofluorophosphate dentifrice
First Posted Date
2015-11-23
Last Posted Date
2017-05-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
488
Registration Number
NCT02612064
Locations
🇬🇧

GSK Investigational Site, Wirral, United Kingdom

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

Phase 4
Completed
Conditions
Gastrointestinal Diseases
Interventions
Drug: IDIAZOLE 20mg DR tabs
Drug: PARIET 20 mg DR tabs
First Posted Date
2015-11-16
Last Posted Date
2018-10-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
70
Registration Number
NCT02605395
Locations
🇪🇬

GSK Investigational Site, Cairo, Egypt

Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)

Phase 1
Completed
Conditions
Pain
Interventions
Drug: Placebo
Drug: Remifentanil
First Posted Date
2015-11-11
Last Posted Date
2015-11-11
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
20
Registration Number
NCT02602002
Locations
🇰🇷

GSK Investigational Site, Seoul, Korea, Republic of

A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

Phase 1
Terminated
Conditions
Amyloidosis
Interventions
Drug: GSK3039294
First Posted Date
2015-11-11
Last Posted Date
2019-09-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
23
Registration Number
NCT02603172
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

Phase 2
Completed
Conditions
Activated PI3K-delta Syndrome
Interventions
First Posted Date
2015-11-01
Last Posted Date
2021-06-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
5
Registration Number
NCT02593539
Locations
🇬🇧

GSK Investigational Site, Cambridge, United Kingdom

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: letetresgene autoleucel (GSK3377794)
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2015-10-28
Last Posted Date
2021-09-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
10
Registration Number
NCT02588612
Locations
🇺🇸

GSK Investigational Site, Houston, Texas, United States

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
Other: Questionnaire
First Posted Date
2015-10-26
Last Posted Date
2017-11-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
278
Registration Number
NCT02586493
Locations
🇺🇸

GSK Investigational Site, Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath